However, it is worth highlighting that allogeneic therapy is likely to grow at a relatively higher CAGR. Retinitis Pigmentosa is Likely to be the Fastest Growing Segment of the Exosome Therapy ...

Inherited eye disorders such as retinitis pigmentosa (RP ... offering a comprehensive approach to RP treatment. The ...

Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regulators about the design ...

CellGenTech’s fourth pipeline product, nerve growth-related factor (NGRF)–GMAC, is designed for the treatment of retinitis pigmentosa ... of microRNA (miRNA) and exosomes to patients.

Nanoscope Therapeutics has reported data from a mid-stage clinical trial that suggests its optogenetic therapy based on ... for incurable eye disease retinitis pigmentosa (RP).

"We are excited by the therapeutic benefits seen in retinitis pigmentosa patients with progressive and permanent loss of photoreceptors and without any treatment option," said Dr. Santosh ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

The global exosome therapy is estimated to grow from USD 0.03 billion in 2029 to USD 1.4 billion by 2040, at a CAGR of 41.1% during the forecast period, till 2035. Owing to the various benefits ...

The global exosome therapy is estimated to grow from USD 0.03 billion in 2029 to USD 1.4 billion by 2040, at a CAGR of 41.1% during the forecast period, till 2035. Owing to the various benefits, such ...